IL33 and asthma: Due to the association of alarmins with driving type 2 immuno-pathophysiological responses to allergens and the expression of their receptors on Th2A cells, ILC2, and other type 2 immune cells, there has been great interest in developing biologics targeting the asthma-associated alarmin triad of TSLP, IL-25, and IL-33.